{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-25-000029","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.817942+00:00","generated_at":"2026-05-24T15:32:15.642930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quanterix Q4 2024 revenue $35.2M (+11% YoY); FY 2025 guidance $140-146M","bullets":["Q4 revenue $35.2M, up 11% YoY; net loss $11.6M vs $8.8M prior year.","Full-year 2024 revenue $137.4M (+12%); net loss $38.5M improved $10.2M.","Ended 2024 with $291.7M cash; 2025 cash usage guided at $55-65M (incl. $20M EMISSION payment).","FY 2025 revenue outlook $140-146M (2-6% growth) excluding Lucent Diagnostics and Akoya impact.","Simoa ONE instrument launch planned by end-2025; FDA breakthrough designation for LucentAD Complete."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-25-000029","json":"https://secwatch.observer/filing/0001503274-25-000029.json","markdown":"https://secwatch.observer/filing/0001503274-25-000029.md","text":"https://secwatch.observer/filing/0001503274-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/0001503274-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/qtrx-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:32:15.642930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}